

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 88407

Title: Editorial: Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of

gastrointestinal tumors

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02441085

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Thailand

Author's Country/Territory: China

Manuscript submission date: 2023-09-23

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2023-11-01 06:51

Reviewer performed review: 2023-11-06 09:49

Review time: 5 Days and 2 Hours

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent[Y] Grade B: Good[] Grade C: Fair[] Grade D: No creativity or innovation





7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors raised awareness of the cardiac toxicity associated with fluoropyrimidine drugs and its harm, identify high-risk groups prone to FIC, and ensure the safe use of drugs in patients with gastrointestinal tumors